Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

152 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Capmatinib efficacy for METex14 non-small cell lung cancer patients: Results of the IFCT-2104 CAPMATU study.
Ferreira M, Swalduz A, Greillier L, du Rusquec P, Curcio H, Raimbourg J, Toffart AC, Gounant V, Couraud S, De Chabot G, Friard S, Hureaux J, Jeannin G, Odier L, Ricordel C, Wislez M, Descarpentries C, Herbreteau G, Missy P, Morin F, Westeel V, Cortot AB. Ferreira M, et al. Among authors: gounant v. Lung Cancer. 2024 Oct;196:107934. doi: 10.1016/j.lungcan.2024.107934. Epub 2024 Aug 24. Lung Cancer. 2024. PMID: 39277916 Clinical Trial.
VEGFR2 and CD34 expression associated with longer survival in patients with pleural mesothelioma in the IFCT-GFPC-0701 MAPS phase 3 trial.
Levallet G, Dubois F, Elie N, Creveuil C, Brosseau S, Danel C, Scherpereel A, Lantuejoul S, Mazières J, Greillier L, Audigier-Valette C, Bergot E, Moro-Sibilot D, Molinier O, Léna H, Monnet I, Morin F, Gounant V, Zalcman G. Levallet G, et al. Among authors: gounant v. Lung Cancer. 2023 Aug;182:107287. doi: 10.1016/j.lungcan.2023.107287. Epub 2023 Jun 26. Lung Cancer. 2023. PMID: 37393757 Clinical Trial.
Metabolic Tumor Volume Assessed by 18F FDG-PET CT Scan as a Predictive Biomarker for Immune Checkpoint Blockers in Advanced NSCLC and Its Biological Correlates.
Dall'Olio FG, Zrafi W, Roelants V, Ambrosini V, Fourquet A, Mitea C, Passiglia F, Bauckneht M, Bonardel G, Conci N, Benitez JC, Arena V, Namour C, Naigeon M, Monnet I, Beshiri K, Hoton D, Dursun S, Danlos FX, Argalia G, Aldea M, Rovera G, Derosa L, Iebba V, Gietema HA, Gounant V, Lacroix V, Remon J, Gautheret D, Chaput N, Job B, Kannouche PL, Velasco-Nuño M, Zitvogel L, Cella E, Chícharo de Freitas JR, Vasseur D, Bettaieb MA, Tagliamento M, Hendriks L, Italiano A, Planchard D, Marabelle A, Barlesi F, Novello S, De Andreis D, Aboubakar Nana F, Ardizzoni A, Zalcman G, Garcia C, Besse B. Dall'Olio FG, et al. Among authors: gounant v. Clin Cancer Res. 2025 Jan 17;31(2):352-364. doi: 10.1158/1078-0432.CCR-24-1993. Clin Cancer Res. 2025. PMID: 39437011
Efficacy of first-line immune checkpoint inhibitors in pulmonary sarcomatoid carcinoma.
Birsen G, Gounant V, Girard N, Cadranel J, Monnet I, Raynaud-Donzel C, Fabre E, Giroux Leprieur E, Leroy K, Damotte D, Alifano M, Arrondeau J, Cremer I, Chapron J, Wislez M. Birsen G, et al. Among authors: gounant v. Transl Lung Cancer Res. 2024 Sep 30;13(9):2212-2221. doi: 10.21037/tlcr-24-263. Epub 2024 Sep 12. Transl Lung Cancer Res. 2024. PMID: 39430330 Free PMC article.
152 results